Brooklyn ImmunoTherapeutics, Inc. (BTX)
After hours:
| Previous Close | 2.7500 |
| Open | 2.7000 |
| Bid | 2.6000 x 800 |
| Ask | 2.6700 x 1000 |
| Day's Range | 2.5800 - 2.7950 |
| 52 Week Range | 2.5800 - 80.6700 |
| Volume | |
| Avg. Volume | 539,996 |
| Market Cap | 138.957M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4470 |
| Earnings Date | Mar. 09, 2022 - Mar. 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- GlobeNewswire
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company’s Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such
- GlobeNewswire
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience (“Factor”) and exclusively licensed to Brooklyn for
- GlobeNewswire
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices
